Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
NCT01748812 · National Institute of Dental and Craniofacial Research (NIDCR) · PHASE1 · terminated · last registry update 2018-07-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Institute of Dental and Craniofacial Research (NIDCR) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FGFR3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-25Results posted on the registry: University of Washington, Doxorubicin Hydrochloride + Ifosfamide (NCT01446809)
- 2019-02-22Phase 3 first posted: Cure HHT, Pazopanib + Placebo oral capsule (NCT03850964)
- 2019-01-29Phase 3 first posted: Boehringer Ingelheim, Nintedanib (NCT03820726)
- 2018-12-21Phase 3 first posted: Institut National de la Santé Et de la Recherche Médicale, France, Nilotinib + Ceritinib (NCT03784014)
- 2018-12-12Phase 3 first posted: QED Therapeutics, a BridgeBio company, BGJ398 + Gemcitabine (NCT03773302)
- 2018-12-10Phase 3 first posted: AB Science, Masitinib + Placebo (NCT03771040)
- 2018-12-06Phase 3 first posted: AB Science, Masitinib + Gemcitabine (NCT03766295)
- 2018-12-03Phase 3 first posted: AB Science, Masitinib + Docetaxel (NCT03761225)
- 2018-11-07Phase 3 first posted: Lakefront Biotherapeutics NV, GLPG1690 + Placebo (NCT03733444)
- 2018-10-18Phase 3 first posted: Lakefront Biotherapeutics NV, GLPG1690 + Placebo (NCT03711162)
- 2018-10-11Results posted on the registry: Boehringer Ingelheim, Nintedanib + Capecitabine (NCT02780700)
- 2018-09-10Results posted on the registry: Boehringer Ingelheim, BIBF 1120 + Placebo (NCT01346540)
- 2018-09-04Phase 3 first posted: Incyte Corporation, Pemigatinib + Gemcitabine (NCT03656536)
- 2018-08-22Results posted on the registry: Noah Hahn, M.D., Dovitinib (NCT01732107)
- 2018-08-06Results posted on the registry: Boehringer Ingelheim, Nintedanib + Docetaxel (NCT02300298)
- 2018-07-26Results posted on the registry: Boehringer Ingelheim, Nintedanib (NCT01619085)
- 2018-07-19Phase 3 first posted: Xynomic Pharmaceuticals, Inc., Pazopanib + Abexinostat (NCT03592472)
- 2018-06-14Phase 3 first posted: AB Science, Masitinib (NCT03556956)
- 2018-01-04Phase 3 first posted: Janssen Research & Development, LLC, Erdafitinib + Vinflunine (NCT03390504)
- 2017-10-18Phase 3 first posted: Boehringer Ingelheim, Nintedanib (NCT03313180)
- 2017-09-14Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Nintedanib + Placebo (NCT03283007)
- 2017-08-24Phase 3 first posted: Incyte Corporation, Pembrolizumab + Epacadostat (NCT03260894)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision